British Journal of Cancer · 2018 · 22 citations · 25 references
MedicineOncologyPathologyGynecologic OncologyTumor PathologyTumor ProgressionAngiogenesisAngiogenesis In CancerCancer ProgressionOvarian CancerTumor GradingTumor MarkersAngiogenic BiomarkersHigh-grade Serous Ovarian CarcinomaImmunohistochemical BiomarkersImmunohistochemical MarkersImmunohistochemical StainingOvarian Cancer BiomarkersOvarian Tumor BiomarkersSerous Ovarian Tumors
High-grade serous ovarian cancer (HGSOC) intratumoural vasculature evolution remains unknown. The study investigated changes in tumour microvessel density (MVD) in a large cohort of paired primary and recurrent HGSOC tissue samples and its impact on patients’ clinico-pathological outcome. A total of 222 primary (pOC) and recurrent (rOC) intra-patient paired HGSOC were assessed for immunohistochemical expression of angiogenesis-associated biomarkers (CD31, to evaluate MVD, and VEGF-A). Expression profiles were compared between pOCs and rOCs and correlated with patients' data. High intratumoural MVD and VEGF-A expression were observed in 75.7% (84/111) and 20.7% (23/111) pOCs, respectively. MVDhigh and VEGF(+) samples were detected in 51.4% (57/111) and 20.7% (23/111) rOCs, respectively. MVDhigh/VEGF(+) co-expression was found in 19.8% (22/111) and 8.1% (9/111) of pOCs and rOCs, respectively (p = 0.02). Pairwise analysis showed no significant change in MVD (p = 0.935) and VEGF-A (p = 0.121) levels from pOCs to rOCs. MVDhigh pOCs were associated with higher CD3(+) (p = 0.029) and CD8(+) (p = 0.013) intratumoural effector TILs, while VEGF(+) samples were most frequently encountered among BRCA-mutated tumours (p = 0.019). Multivariate analysis showed VEGF and MVD were not independent prognostic factors for OS. HGSOC intratumoural vasculature did not undergo significant changes during disease progression. High concentration of CD31(+) vessels seems to promote recruitment of effector TILs. The study also provides preliminary evidence of the correlation between VEGF-positivity and BRCA status.
25
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Integrated genomic analyses of ovarian carcinoma
Debra Bell, Andrew Berchuck, Narciso Olvera et al. · Nature · 2011 · 8.2K citations · Full text
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Donald R. Senger, Stephen J. Galli, Ann M. Dvořàk et al. · Science · 1983 · 4K citations
Medicine, Biochemistry, Oncology +13
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine · 2011 · 2.4K citations · Full text
Medicine, Gynecology, Oncology +11